CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models

enthalten in: Molecular cancer therapeutics | 2018

von Drake, P. | Carlson, A. | McFarland, J. | +7